Melanocortin peptide pre-treatment prevented chondrocyte death following mechanical impact to cartilage and led to a marked reduction of pro-inflammatory cytokines, whilst prompting the production of anti-inflammatory/pro-resolving cytokine IL-10.
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Introduction
Osteoarthritis (OA) is a disease affecting load-bearing joints, characterised by selfperpetuating low-grade inflammation and degradative processes within the articular cartilage of affected joints. It is a leading cause of disability affecting almost every age group, with prevalence increasing dramatically over the age of 50, affecting~60% of people in this age group. With increasing age, obesity and longer life spans, OA represents an ever-increasing socio-economic burden [1] , for which at present there is no cure.
Traumatic joint injuries are a major risk factor for the development and progression of OA [2] and increase the risk of arthritis 5 to 17-fold [3, 4] . Knee traumas, in particular, represent over 40% of all sports injuries [5] [6] [7] and often result from traffic accidents with surgical restoration of joint stability not preventing future arthritis development [8] [9] [10] [11] . The incidence of post-traumatic arthritis is therefore high -creating insistent demand for pharmacological intervention, directed at limiting the progression and propagation of destructive processes taking place in the early stages post-injury [2, 12] .
In a healthy joint, the smooth surface provided by articular cartilage promotes near frictionless joint movement allowing the joint to withstand tensile and compressive forces arising from movement [13] . Mechanical loading within physiological limits is an essential stimulus for chondrocytes to produce extra-cellular matrix (ECM), capable of withstanding normal levels of stress and is responsible for triggering the synthesis, exportation and degradation of ECM components -collagen and proteoglycans [14] . However, when the joint/cartilage experiences mechanical stresses above the normal physiological range and/or frequency, such as in impact trauma, this results in significant chondrocyte death attributed to mechanical necrosis [15] and apoptotic processes [16, 17] that could trigger the development of OA [18] .
The effect of impact trauma on the functionality and metabolism of chondrocytes is receiving increasing attention [16, 17, 19, 20] , because within mature articular cartilage, chondrocytes do not generally undergo cell division [21, 22] . Additionally, OA is featured by reduced cellularity [21, [23] [24] [25] [26] [27] [28] [29] , a fact that is thought to contribute to the inability of the remaining chondrocytes to maintain normal matrix synthesis, thereby contributing to cartilage degradation [30] .
Impact injury is associated with increased production of pro-inflammatory cytokines by affected chondrocytes [31] . Abnormal mechanical forces cause adult chondrocytes to initiate production of a large number of pro-inflammatory mediators including the cytokines TNF- and IL-1β [18, 32] , which in combination with reactive oxygen species and lipid-derived
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A c c e p t e d M a n u s c r i p t 5 inflammatory stimuli (including prostaglandins and leukotrienes) increase the catabolic activity of and ultimately kill chondrocytes distant from the impact-injury site [33] [34] [35] . This eventually leads impaired ECM synthesis, cartilage degradation and, ultimately, development of OA [36, 37] .
Currently there is no treatment for OA, capable of reducing the degradation of cartilage or improving its function. Current treatment relies largely on conservative pain management strategies (analgesics and non-steroidal anti-inflammatory drugs (NSAIDs)). These are only temporarily effective with numerous side effects, and if unsuccessful leave expensive joint replacement surgery as the last resort. To find highly effective drugs with an enhanced safety profile for OA treatment is imperative. Development of compounds displaying both anti-inflammatory effects along with pro-resolving/chondroprotective properties represents an exciting therapeutic strategy.
Unravelling the mediators that provide tissue protection and developing peptide-based drugs targeted at the resolution phase of inflammation is an exciting concept [38, 39] . Amongst a host of such mediators are the melanocortins. The melanocortin peptides have long been
shown to display anti-inflammatory effects from the early seminal studies by Lipton demonstrating their anti-pyretic effects [40] and their potency -they are 25,000x more potent than paracetamol [41] . Over the last four decades a substantial body of evidence has exposed their beneficial effects in models of asthma [42] [43] [44] , inflammatory bowel disease [45] [46] [47] , cardiovascular disease [48] [49] [50] [51] [52] [53] , and neuroprotection [54-56] to name just a few areas.
Within the arthritic field, the melanocortin system has been evaluated in patients with RA and juvenile chronic arthritis; increased -MSH levels were detected in synovial fluid, with a correlation suggesting that higher levels of -MSH decrease the level of inflammation observed [57] . These important findings highlighted the prospect of harnessing the antiinflammatory effects of -MSH for arthritic diseases and soon after the beneficial effects of the peptide were proven in a model of adjuvant-induced arthritis [58], while more recently, it was found to be beneficial in models of gouty and rheumatoid arthritis (RA) [59] [60] [61] [62] .
However, only a handful of studies have evaluated their effects in chondrocytes and OA [63] , [64] . This surprising lack of interest in evaluating the potential of these molecules as a treatment for OA may stem from the fact that although inflammation is considered causal to both RA and gouty arthritis, OA has historically been perceived as simply a condition of natural 'wear and tear', with inflammation not regarded as a major contributor in the development of the pathology. Nevertheless, this initial viewpoint is currently changing [32, 64] .
A c c e p t e d M a n u s c r i p t
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Melanocortin peptides are derived from the larger, pre-cursor pro-opiomelanocortin Here, we have demonstrated for the first time the ability of melanocortins to limit the progression of mechanical impact-induced chondrocyte death. In addition, the peptides inhibited the resulting production of pro-inflammatory cytokines in both in situ and TNF--stimulated freshly-isolated articular chondrocytes, while promoting the release IL-10, thereby aiding in the resolution of inflammation and conferring further protection against cartilage damage.
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Materials & Methods
Unless specified otherwise, all reagents were purchased from Sigma-Aldrich Inc., (Poole, UK). and Streptomycin (50.0 µg/mL) at 37ºC, and 5% CO 2 in the absence of foetal calf serum (FCS; Invitrogen, Paisley, UK) and cultured within 24h or used for impact studies [67] .
Mechanical loading of tissue
A vertical drop tower previously shown to cause impact damage to cartilage explants in aseptic conditions [30] , was used to deliver a single defined impact (137g weight dropped from a height of 10 cm), equivalent to 1.14 N, 6.47 kPa (assuming linear acceleration), to individual bovine articular cartilage explants [30] . The Isolated, pre-weighed articular cartilage explants (~5mm ]--MSH (3.0 µg/mL), or dexamethasone (10 -6 M), for 1h prior to impact. Individual cartilage explants were then positioned with the synovial (articular) surface uppermost on the drop tower base and exposed to single impact. Samples exposed to accidental multiple impacts were discarded.
Explants were then immediately returned to the same media, containing the melanocortin
]--MSH) or dexamethasone for 6h, the reaction was then terminated and cell culture supernatants collected and stored at -20ºC prior to cytokines analysis by ELISA (R&D Systems Europe Ltd, Oxford, UK) as previously described [64] .
Following treatment, the cartilage explants were transferred to dry 10 cm 2 plastic dishes, positioned flat on the dish and viewed perpendicular to the synovial surface. The tissue was immobilized in the center of the dish using a small drop of cyanoacrylate glue (Bostik, UK) [30] , and incubated on a heated microscope stage (37ºC) for 30 min in fresh DMEM media A c c e p t e d M a n u s c r i p t 8 confocal laser scanning microscopy (CLSM) was used (Leica Microsystems, Milton Keynes, UK).
Confocal Analysis
Microscopy and determination of chondrocyte cell viability in situ
Images were acquired using an upright microscope attached to a Leica SP2 CLSM and associated Leica software. Calcein and PI excited using a 488 nm (argon laser), with an emission measured at a bandpass of 510-535 nm and PI excited using a 543nm (He-Ne laser) with an emission recorded at a bandpass of 660-709nm. Chondrocytes in cartilage explants were viewed with a low power magnification (x10 air objective) for in situ chondrocyte viability measurements. Z-series of individual images of the chondrocytes were taken at 10 µm z-steps. Scanning speed was 0.6 Hz with double frame integration, double line averaging for 512 x 512 pixel image with viable cells appearing green and dying cellsred [30] .
Confocal data analysis -in situ chondrocyte viability measurements
Cell viability prior to and post impact was evaluated using Imaris 7. for 10 days prior to experimentation [67] . All experiments were performed with freshly isolated chondrocytes (at passage 0) in serum-free conditions as described above.
In vitro cell stimulations
Following the 
Statistics and Receptor Nomenclature
All data are reported as mean ± SEM of n observations, using at least 3 experiments with 4 determinations per group. Statistical evaluation was performed using analysis of variance ANOVA (Prism GraphPad Software) incorporating Bonferroni or Dunnet's Post-tests to allow for post-hoc analyses, with a probability p value < 0.05 taken as significant. Receptor nomenclature for melanocortin receptors was in accordance with the "Guide to receptors and Channels (GRAC)" [70] .
A c c e p t e d M a n u s c r i p t 10 3 Results
Single impact to cartilage explants causes choncrocyte death and increase production of pro-inflammatory cytokines
Areas of cartilage/chondrocyte injury caused by impact force are shown in Figure 1A (nonimpacted) versus Figure 1B (impacted). Spot analysis indicated a 4.5-fold increase of cell death in articular cartilage explants subjected to a single blunt impact (13.5±1.7%) compared to 2.95% cell death in non-impacted explants (p<0.05).
Single blunt impact injury to bovine articular cartilage explants caused a dramatic increase in the release of the potent pro-inflammatory cytokines IL-1 from the resident chondrocytes ( Figure 1 ). The cartilage injury initiated a 19.5-fold upsurge in production of IL-1 from 18±5 pg/mL/g to 351±24 pg/mL/g in impacted explants (p<0.0001; Figure 1D ). Levels of IL-6 rose 7.5-fold to 448±20 pg/mL/g above basal levels (59±9 pg/ml/g; p<0.0001) and IL-8 production was increased by 3-fold to 294±14 pg/mL/g, as compared to non-impacted control tissue (97±11 pg/mL/g; p<0.0001; Figure 1F ).
-MSH and [DTRP 8 ]--MSH prevent articular chondrocyte death caused by impact injury of cartilage explants and reduce pro-inflammatory cytokines production
Previously, we have suggested that melanocortins have a chondroprotective potential due to their ability to reverse TNF--induced chondrocyte death [64] . As an addition to this work, 50% and 58% respectively (p<0.0001; Figure 2C ). Congruently, IL-6 production was also modulated by -MSH, [DTRP 8 ]--MSH and Dex, whereby the drugs led to 65%, 71% and 84% reduction in the cytokine production (p<0.0001; Figure 2D ) and IL-8 levels were inhibited by 53%, 54% and 65%, respectively (p<0.0001; Figure 2D ).
Notably, treatment of non-impacted articular cartilage with -MSH, D[TRP] 8 --MSH or Dex had no detectable effect on chondrocyte viability ( Figure 3A , B, E) and did not alter the M a n u s c r i p t 11 production of key pro-inflammatory cytokines (IL-1, IL-6 and IL-8) within the time point selected for these experiments (Figure 3C-E) .
TNF- stimulates cytokine and chemokine release from bovine chondrocytes
Stimulation of freshly-isolated primary bovine chondrocytes with TNF- (0-80 pg/mL) led to significant increases in cytokine release (Table 2) . TNF- caused a concentration-dependent increase in IL-6 with a maximal release observed at 80 pg/ml TNF- of 347±30 pg/mL (p<0.001), while a bell-shaped response was observed for both IL-1 and IL-8, with 60 pg/mL TNF- causing a near maximal or maximal release with concentrations of 46±3 pg/mL IL-8 (p<0.01) and 22±0.2 pg/mL IL-1 (p<0.05), compared to untreated controls (0.82±0.06 pg/mL and 2.81±1.46 pg/mL, respectively; Table 2 ). g/mL) potently reduced the production of IL-, triggering a bell-shaped decrease of 61%, 76% and 39%, respectively (p<0.05). In contrast, the MC 3/4 antagonist / MC 1 agonist, SHU9119, elicited just a modest inhibition of IL-1release at 3 g/mL (23% compared to TNF- treated controls; Figure 4A ).
-MSH
Markedly, IL-6 levels were significantly modulated by -MSH with 1 g/mL causing IL-6 production to be abrogated by 93% (from 174±15 pg/mL to 13±1 pg/mL; p<0.001), with higher concentrations of -MSH, (3, 10 and 30 g/mL), prompting a reduced but still significant reduction in the release of IL-6 (87%, 76% and 48%, respectively), compared to TNF--treated controls. Similar results were observed following pre-treatment with [DTRP 8 ]--MSH (1 -10 g/mL) with maximal inhibition of 72% at 3 g/mL, while 1 and 10 g/mL caused 40% and 48% reduction, respectively (p<0.001). Higher concentrations of [DTRP 8 ]--MSH (30 g/mL) produced only a small, statistically insignificant, reduction in cytokine production, whilst SHU9119 failed to inhibit IL-6 release at all concentrations tested ( Figure   4B ).
[DTRP 8 ]--MSH attenuated TNF--induced IL-8 release ( Figure 4C ) in a bell-shaped manner, with maximal effect at 3 µg/mL, causing a 69% reduction in IL-8 secretion (p<0.01).
At 10 and 30 g/mL, the peptide reduced the chemokine release by 57% and 45%, 
-MSH and [DTRP] 8 --MSH enhance IL-10 production by activated primary chondrocytes
Production of IL-10 was undetectable in both non-stimulated and TNF--activated freshly isolated primary bovine chondrocytes ( Figure 6 ). However, pre-treatment with both -MSH M a n u s c r i p t 13 
Discussion
Although the exact pathogenesis of OA is not fully understood, abnormal mechanical stresses including sport injuries and trauma all play a role for development of OA [71] . Blunt trauma to articular cartilage, resulting from accidents or sport injuries are associated with high levels of chondrocyte death and is associated with local inflammatory reactions, thereby representing a major risk factor for the development of post-traumatic OA, which despite constant improvement of surgical techniques, still accounts for ~12% of all cases of OA [72] .
Given the significance of trauma for the development of OA, the effect of a single blunt mechanical impact on chondrocyte viability and rates of pro-inflammatory mediator synthesis were determined. Cell death arising from the single impact has been previously revealed to be both temporal and spatial -an initial rapid phase rising from the mechanical trauma occurs at the tissue fissures and a slower wave of cell death takes place away from the impact lesion, thereby suggesting the release of soluble intercellular singalling molecules [73] .
This study has taken a particular interest in the events occurring in areas of cartilage that are distant to the impact lesion and therefore not directly affected by the mechanical impact. In non-impacted cartilage,~3% of chondrocytes were non-viable, possibly due to the excision of the explant from the bone and remained constant in the first 6h post-excision (data not shown). Single blunt impact to cartilage explants triggered surface fissuring and stressdependent loss of chondrocytes' viability along tissue cracks (data not shown) [30] . We detected significant 4.6-fold increase in chondrocytes, resident in the morphologically normal area of the impacted cartilage explant. In addition to loss of viability, chondrocytes responded to injury through increasing the production of IL-1, IL-6 and IL-8 by and 17-, 8-and 3-fold, respectively.
These data clearly demonstrate that chondrocytes in injured cartilage explants are actively producing wide variety of pro-inflammatory cytokines well above basal levels, which may activate neighbouring chondrocytes in an auto and paracrine manner. It is well described that elevated levels of pro-inflammatory cytokines provoke resident chondrocytes to initiate pathological expression and secretion of inflammatory mediators [18, 32] and cartilagedegrading proteases [34, 74] . In addition, excess stimulation of chondrocytes with proinflammatory cytokines such as TNF- and IL-1 induces apoptosis via activation of caspase-driven pathways [64, 75] .
Impact injury has been directly associated with increased production of pro-inflammatory cytokines by affected chondrocytes. Abnormal mechanical forces appear to 'awaken' adult A c c e p t e d M a n u s c r i p t 14 chondrocytes from a state of low metabolic activity and stimulate the production of a large number of pro-inflammatory molecules including TNF-, IL-1β [18, 32] We have previously proposed that melanocortin peptides display potent chondroprotective, anti-apoptotic and anti-inflammatory effects through their ability to inhibit TNF--induced chondrocyte apoptosis and inflammation [64] . However, in spite of the potential of melanocortin peptides to limit inflammation, few studies have looked at their chondroprotective properties. We have recently demonstrated that both the melanocortin receptor pan-agonist -MSH and [DTRP 8 ]--MSH (structures shown in Table 1 ), which shows selectivity for MC 3 , ameliorate TNF--induced chondrocyte apoptosis and the release of pro-inflammatory cytokines and MMP's [64] . Now, we describe the ability of the of melanocortins to: 1) prompt a homeostatic control over impact-induced inflammatory cytokine production, 2) confine chondrocyte death and cartilage damage to injury site, whilst
3) preserving the viability of chondrocytes in adjacent non-impacted areas, and 4) prompting the production of anti-inflammatory cytokine IL-10. reduce cytokine relase is well documented both in vitro [63, 64] and in vivo models of inflammation [60] [61] [62] 76] , this is the first time their protective properties have been studied in an in situ model of mechanically-induced cartilage injury, and the first indication that targeting the melanocortin receptor system for the development of potential treatment of mechanical/sports injuries and trauma is a viable option.
-MSH and [DTRP
The sensitivity of primary bovine chondrocytes to inflammatory cytokines was further corroborated in vitro -significant increase in production of IL-1, IL-6 and IL-8 by freshlyisolated articular chondrocytes was detected in response to TNF- (Table 2 ). This finding has been previously reported in a human chondrocytic cell-line [64] and primary canine chondrocytes [77] , whilst in vivo these changes lead to destruction of cartilage [78] . M a n u s c r i p t
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In order to associate the observed effects to a specific receptor from the melanocortin family, the peptide SHU9119 was used, which antagonizes with high-specificity MC 3 /MC 4 , while displaying weak agonist profile towards MC 1 /MC 5 . Alone, SHU9119 caused a modest inhibition of IL-1 but had no effect on TNF--induced IL-6 or IL-8 production, consistent with its dual agonist/antagonist nature. Remarkably, while SHU9119 was unable to block the effect of -MSH, it abridged the anti-inflammatory activity of D[TRP] 8 --MSH, thus suggesting a potential role for MC 3 in chondroprotection, which agrees with previous studies reporting MC 3 agonist activity of this peptide [51, 76, 79] . Moreover, at higher concentrations of -MSH, the presence of SHU9119 synergistically reduced IL-6 release, thereby signifying that SHU9119 may be concerting efforts with -MSH via either activation of MC 1 and/or MC 5 . Since these effects were observed with the highest concentration of -MSH only, a possibility exists that MC 1 sensitization is causing the receptor to internalize, a welldescribed feature of GPCRs such as the  2 -adrenergic receptor [80] [81] [82] , while an upregulation in MC 5 may be a compensatory mechanism. However, the exact mechanism needs to be further elucidated.
An important feature of the melanocortin peptides that has captured the attention of academia and industry alike is their well-described ability to promote resolution of inflammation. They reduce the host's inflammatory response by modulating the production of pro-inflammatory mediators [59, 63, 64] , and maybe even more importantly, by actively stimulating the resolution phase of inflammation through inducing IL-10 and heme oxygenase-1, which possess powerful anti-inflammatory and pro-resolving properties [83, 84] . Protective effects have been demonstrated extensively in murine models of gout [59] [60] [61] and RA [62] . In addition to these well reported effects in models of arthritis, the melanocortin peptides display a plethora of effects in other disease pathologies For example, in models of cerebral ischemia, -MSH decreased TNF- and IL-1 [85] , ACTH-derived peptides have been shown to downgrade nitric oxide [86] and free radicals production [79, 87] , whilst inducing IL-10 [55] and reducing apoptotic effects [54] . The ability of melanocortins to provoke similar responses in diverse disease models highlights their importance in restoring homeostatic balance to many tissues throughout the entire body. These findings are additionally supported by in vitro observations in primary human articular chondrocytes [63] and chondrocytic cell-lines [64] . primary chondrocytes from both OA and healthy human cartilage. The pharmacological data shown emphasize a potential chondroprotective/anti-inflammatory role for MC 1 , but could also implicate a role for MC 3 in primary bovine chondrocytes, akin to that observed in human C-20/A4 chondrocytes [64] .
-MSH
In this study, chondrocyte stimulation was conducted prior to impact as an initial attempt to assess the ability of the melanocortins to exert similar protective effects at tissue level (cartilage), as those observed at cellular level using the C20/A4 chondrocyte cell-line [64] . It is important to note that immediately after impact, cartilage explants were returned to media containing melanocortin peptides and left to bathe in it for the duration of the incubation (6h), therefore providing wider window for the peptides to exert effects. Nonetheless, evaluating their effects post-impact is crucial to fully appreciate the therapeutic potential of these compounds for trauma injury and studies aimed at addressing this point have already commenced.
Osteoarthritis resultant from traumatic joint injury is a serious complication, which leaves the injured individuals -frequently young people involved in sports accidents or car crasheswith lifetime of palpable pain, disability, leading to various degree of social isolation. Yet, current treatment options are inadequate, largely focused on pain management and often fail to address articular tissue degeneration. Since mechanical injury to joints leads to cartilage degeneration through chondrocyte death and matrix breakdown, prospective treatments targeting these pathways should be examined. A human knee joint with injured articular cartilage and meniscus (hand drawing for illustrative purposes only) -melanocortin peptides were able to prevent the progression of trauma-induced chondrocyte death and the consequential propagation of pro-inflammatory A c c e p t e d M a n u s c r i p t 17 cytokines into non-impacted areas of cartilage explants, all the while promoting the release of reparative pro-resolving molecule.
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In this study we describe the rapid response of articular chondrocytes to mechanical trauma -the speedy propagation of cartilage inflammation and chondrocyte death, and accentuate on the ability of melanocortin peptides -MSH and [DTRP 8 ]--MSH to temper this response.
We report that activation of both MC 1 and MC 3 receptor subtypes prevents the progression of trauma-induced chondrocyte death and the consequential propagation of proinflammatory cytokines into non-impacted areas of cartilage, all the while promoting the release of reparative pro-resolving molecules ( Figure 7) . Altogether, we propose that melanocortins could provide novel chondroprotective therapies for the prevention and treatment of post-traumatic osteoarthritis.
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A c c e p t e d M a n u s c r i p t 27 Isolated primary bovine chondrocytes were stimulated with TNF- (0 -80 pg/mL). Cell-free supernatants were collected 6h post-stimulation and analysed for IL-1, IL-6 and IL-8 by ELISA. Data are presented as Mean ± SEM of n = 4 independent experiments repeated in triplicate, *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 vs. untreated controls.
